Cargando…

Use of Selective Alternative Therapies for Treatment of OCD

About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several side effects were reported. This systematic review was conducted to evaluate the efficacy and tolerability of alternative drugs and assess the possibilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Iman, Jaura, Taimoor Asif, Tukruna, Alaa, Arif, Aabiya, Tebha, Sameer Saleem, Nasir, Sameen, Mukherjee, Dattatreya, Masroor, Nadia, Yosufi, Abubakr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083036/
https://www.ncbi.nlm.nih.gov/pubmed/37041856
http://dx.doi.org/10.2147/NDT.S403997
_version_ 1785021425085579264
author Khan, Iman
Jaura, Taimoor Asif
Tukruna, Alaa
Arif, Aabiya
Tebha, Sameer Saleem
Nasir, Sameen
Mukherjee, Dattatreya
Masroor, Nadia
Yosufi, Abubakr
author_facet Khan, Iman
Jaura, Taimoor Asif
Tukruna, Alaa
Arif, Aabiya
Tebha, Sameer Saleem
Nasir, Sameen
Mukherjee, Dattatreya
Masroor, Nadia
Yosufi, Abubakr
author_sort Khan, Iman
collection PubMed
description About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several side effects were reported. This systematic review was conducted to evaluate the efficacy and tolerability of alternative drugs and assess the possibility of their use as treatment options for obsessive-compulsive-disorder. The Scientific databases PubMed, Science Direct, Google Scholar, Cochrane, Directory of Open Access Journals, MedRxiv and BioRxiv, were searched from inception to March 2022, using appropriate search strategies for each drug and following the Prisma guidelines 2020. Studies were selected according to the already set criteria and assessed for bias. Data were extracted, and descriptive and continuous data were analyzed and presented as frequency/percentage and mean. A total of 16 observational and interventional studies were included for data extraction. The studies focused on four drugs, Psilocybin (n=4), Cannabis (n=7), Nicotine (n=3), and Morphine (n=2), that were used to test out their effect on OCD symptoms. Overall, the majority of the studies showed promising results by documenting a reduction in Y-BOCS scores. However, few subjects, specifically those using nicotine or Cannabis, did not affect their condition or self-reported worsening symptoms. Few side effects were also noticed. This systematic review found that the drugs mostly showed a positive response. All Psilocybin and morphine users, 88.2% and 74.1% of the nicotine and Cannabis users, respectively, reported experiencing the positive effect of these drugs, indicating that these drugs have the potential to be used in the management of OCD. However, further research is required in this arena to thoroughly understand the mechanism of action by which these drugs produce their therapeutic effect. Policies to destigmatize and encourage clinical trials with these drugs are crucial for exploring the use of these drugs as a treatment option for OCD.
format Online
Article
Text
id pubmed-10083036
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100830362023-04-10 Use of Selective Alternative Therapies for Treatment of OCD Khan, Iman Jaura, Taimoor Asif Tukruna, Alaa Arif, Aabiya Tebha, Sameer Saleem Nasir, Sameen Mukherjee, Dattatreya Masroor, Nadia Yosufi, Abubakr Neuropsychiatr Dis Treat Review About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several side effects were reported. This systematic review was conducted to evaluate the efficacy and tolerability of alternative drugs and assess the possibility of their use as treatment options for obsessive-compulsive-disorder. The Scientific databases PubMed, Science Direct, Google Scholar, Cochrane, Directory of Open Access Journals, MedRxiv and BioRxiv, were searched from inception to March 2022, using appropriate search strategies for each drug and following the Prisma guidelines 2020. Studies were selected according to the already set criteria and assessed for bias. Data were extracted, and descriptive and continuous data were analyzed and presented as frequency/percentage and mean. A total of 16 observational and interventional studies were included for data extraction. The studies focused on four drugs, Psilocybin (n=4), Cannabis (n=7), Nicotine (n=3), and Morphine (n=2), that were used to test out their effect on OCD symptoms. Overall, the majority of the studies showed promising results by documenting a reduction in Y-BOCS scores. However, few subjects, specifically those using nicotine or Cannabis, did not affect their condition or self-reported worsening symptoms. Few side effects were also noticed. This systematic review found that the drugs mostly showed a positive response. All Psilocybin and morphine users, 88.2% and 74.1% of the nicotine and Cannabis users, respectively, reported experiencing the positive effect of these drugs, indicating that these drugs have the potential to be used in the management of OCD. However, further research is required in this arena to thoroughly understand the mechanism of action by which these drugs produce their therapeutic effect. Policies to destigmatize and encourage clinical trials with these drugs are crucial for exploring the use of these drugs as a treatment option for OCD. Dove 2023-04-05 /pmc/articles/PMC10083036/ /pubmed/37041856 http://dx.doi.org/10.2147/NDT.S403997 Text en © 2023 Khan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Khan, Iman
Jaura, Taimoor Asif
Tukruna, Alaa
Arif, Aabiya
Tebha, Sameer Saleem
Nasir, Sameen
Mukherjee, Dattatreya
Masroor, Nadia
Yosufi, Abubakr
Use of Selective Alternative Therapies for Treatment of OCD
title Use of Selective Alternative Therapies for Treatment of OCD
title_full Use of Selective Alternative Therapies for Treatment of OCD
title_fullStr Use of Selective Alternative Therapies for Treatment of OCD
title_full_unstemmed Use of Selective Alternative Therapies for Treatment of OCD
title_short Use of Selective Alternative Therapies for Treatment of OCD
title_sort use of selective alternative therapies for treatment of ocd
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083036/
https://www.ncbi.nlm.nih.gov/pubmed/37041856
http://dx.doi.org/10.2147/NDT.S403997
work_keys_str_mv AT khaniman useofselectivealternativetherapiesfortreatmentofocd
AT jaurataimoorasif useofselectivealternativetherapiesfortreatmentofocd
AT tukrunaalaa useofselectivealternativetherapiesfortreatmentofocd
AT arifaabiya useofselectivealternativetherapiesfortreatmentofocd
AT tebhasameersaleem useofselectivealternativetherapiesfortreatmentofocd
AT nasirsameen useofselectivealternativetherapiesfortreatmentofocd
AT mukherjeedattatreya useofselectivealternativetherapiesfortreatmentofocd
AT masroornadia useofselectivealternativetherapiesfortreatmentofocd
AT yosufiabubakr useofselectivealternativetherapiesfortreatmentofocd